ReviewInternational journal of nanomedicine2026
Nanomedicine-Based Strategies for Multiple Myeloma Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) belongs to the hematological malignancies and the overall incidence of MM is on the rise across the world. Over the last few decades, increased attention has been paid to the development and pathogenesis of MM. Significant changes have also been witnessed in the paradigm for the treatment of MM, including proteasome inhibitors, immunomodulators and anti CD38 monoclonal antibodies, which have significantly improved the survival of patients. The increasing focus on nanomedicine stems from its capacity to enhance the treatment of MM-by reducing systemic side effects and enabling more precise therapeutic targeting. This review summarizes current advances in nanomedicine-based treatment options for MM and disscusses the superior efficacy of biomimetic nanoparticles exploiting bone marrow homing. It also covers the potential of mRNA nano‑vaccines (eg, Galsomes and BCMA‑mRNA LNPs) and the improved safety profiles of liposomal formulations compared to free drugs. This review will provide further insight into developing treatment strategies for MM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.